Related Experiment Videos
Immune pressures drive the promoter hypermethylation of neoantigen genes
Ming Yi1, Bing Dong2, Qian Chu1
11Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030 China.
Abstract:
Cancer cells with strong immunogenicity are susceptible for elimination by cancer immunoediting, while the subpopulations with weak immunogenicity survive. As a result, a subset of cancer cells evade the immune attack and evolve into overt clinical lesions. During cancer evolution, it has been well established that multiple alterations such as the dysfunction of antigen presentation machinery and the upregulation of immunosuppressive signals (e.g. PD-L1) play important roles in immune escape. Recently, promoter hypermethylation of neoantigen genes has been proposed to be a vital mechanism of immunoediting. This epigenetically mediated immune evasion enriches the mechanisms of carcinogenesis.
Insights
Cancer cells with weak immunogenicity survive immune attack through epigenetic changes like promoter hypermethylation of neoantigen genes. This immune evasion mechanism contributes to cancer development and progression.
Area of Science:
- Cancer immunology
- Epigenetics
- Tumor microenvironment
Background:
- Cancer immunoediting eliminates immunogenic cells, allowing less immunogenic subpopulations to survive and form clinical lesions.
- Immune escape involves antigen presentation defects and immunosuppressive signals like PD-L1.
Discussion:
- Promoter hypermethylation of neoantigen genes is a newly identified mechanism for cancer immune evasion.
- Epigenetic modifications, specifically hypermethylation, can silence neoantigen expression, rendering cancer cells invisible to the immune system.
- This epigenetically mediated immune evasion complements known mechanisms, enriching cancer's ability to escape immune surveillance.
Key Insights:
- Weakly immunogenic cancer cell subpopulations survive immunoediting.
- Promoter hypermethylation of neoantigen genes is a critical epigenetic mechanism for immune escape.
- Epigenetic silencing of neoantigens contributes to tumor progression and clinical lesion development.
Outlook:
- Investigating epigenetic regulation of neoantigens can reveal novel therapeutic targets.
- Understanding these immune evasion strategies may lead to improved cancer immunotherapy approaches.
- Further research into epigenetically mediated immune evasion is crucial for advancing cancer treatment.